So if BMS are paying $4b to get 35% of Nektar's drug and Merck are paying $450m to get all of vla's (this is Merck's offer less our cash). That means BMS are paying over 25 times what Merck are paying proportionally.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025